This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Afatinib* has been extensively investigated as part of the LUX-Lung clinical trial programme.
Afatinib’s Clinical Trials In NSCLC
The approval of afatinib for the treatment of TKI-naïve patients with locally advanced or metastatic, EGFR mutation-positive NSCLC is based on the global Phase III LUX-Lung 3 study1 and its Phase III sister trial in Asia, LUX-Lung 6.2
Afatinib is also indicated for the treatment of patients with locally advanced or metastatic squamous NSCLC that has progressed on or after platinum-based chemotherapy, based on the Phase III LUX-Lung 8 study.3
The approval of afatinib for the treatment of TKI-pretreated patients is based on the Phase IIB/III LUX-Lung 1 study.4
The following table shows the clinical trials of afatinib in lung cancer; you can find links to further information on this site and published papers.
Ongoing clinical trials
Afatinib plus cetuximab6–8
The combination of afatinib and cetuximab has been investigated in two Phase Ib clinical studies.6-8 These showed the maximum tolerated dose for the combination to be afatinib 40 mg/day plus cetuximab at either 500 mg/m2 Q2W or 250 mg/m2/week.6 In one of these studies, in 126 patients with stage IIIB/IV EGFR mutation-positive NSCLC who had progressed on erlotinib or gefitinib, ORR was 29% and median PFS was 4.7 months, with no reported difference in ORR or PFS according to T790M status.6,7
In the second study, in 49 patients with squamous NSCLC (n=12), head and neck squamous cell carcinoma (HNSCC; n=15) or other solid tumours (n=22), treatment with afatinib* plus cetuximab resulted in a disease control rate of 75% in patients with squamous NSCLC and 55% in the overall population.6,8
The safety profile of afatinib plus cetuximab was predictable and manageable in both studies. Tolerability-guided dose adjustment of afatinib reduced the frequency and intensity of treatment-related AEs.6
Sequist LV, et al. J Clin Oncol 2013;31(27):3327–34.
Wu YL, et al. Lancet Oncol 2014;15(2):213–22.
Soria JC, et al. Lancet Oncol 2015;16(8):897–907.
Miller VA, et al. Lancet Oncol 2012;13(5):528–38.
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT02597946 (Accessed: August 2017).
Soria J-C, et al. Poster presented at CSCO 2017 (Poster P24).
Clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/record/NCT01090011 (Accessed: October 2017).
Clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/record/NCT02020577 (Accessed: October 2017).
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue